Butyrate, a short-chain fatty acid made by gut bacteria, is found at higher levels in the blood of people with IgA nephropathy, and a gut bacterium called Blautia tracks with worse kidney measures, in a multicenter analysis spanning six tertiary hospitals and more than 280 participants.
The findings give the gut-kidney axis its detailed look in this disease. IgA nephropathy (IgAN) is increasingly linked to gut mucosal immune dysregulation. It is a multicenter cross-sectional study.
Researchers have said that the associated microbial and metabolic features remain inconsistently characterized, because IgA is produced there. What remained inconsistent across earlier studies was which microbes and which metabolic products actually distinguish patients from healthy people. This study points to a specific pattern: enrichment of Blautia and the Ruminococcus gnavus group, altered pyruvate metabolism, and elevated circulating butyrate and lactate.
The clinical implication is a possible mechanism, not a treatment. In laboratory testing, butyrate changed the behavior of B cells taken from patients — increasing the proportion carrying the CCR9 receptor and decreasing the proportion producing the regulatory signal IL-10. The authors’ conclusion, as stated in the paper, is that circulating butyrate may contribute to mucosal immune dysregulation in IgAN through altered B-cell homing and impaired regulatory function.
Study finds gut bacteria links to kidney disease markers
- This is a study of associations, not a cure. It found that people with IgA nephropathy carry different gut bacteria and higher blood levels of butyrate than healthy kidney donors.
- Higher Blautia levels lined up with blood pressure, serum creatinine, and urine protein-to-creatinine ratio in IgAN.
- No probiotic, supplement, or diet change is validated by this research. Talk to your nephrologist before changing anything based on headlines.
How the study was built
The design matters for how much weight the findings can carry. Fecal samples came from 187 participants in the discovery stage — 100 with IgAN, 30 with membranous nephropathy, and 57 controls — plus a replication cohort of 96 IgAN patients and 46 controls, all recruited across six tertiary hospitals. Controls were healthy living kidney donors who passed standard donor screening.
All samples underwent 16S rRNA sequencing. Patients differed from controls in beta diversity, but not in alpha diversity. Among eight bacterial genera and 31 predicted metabolic pathways associated with the disease, three signals held up in the replication cohort: Blautia (P = 0.008), the Ruminococcus gnavus group (P = 0.011), and pyruvate metabolism (ko00620) (P = 0.005).
The metabolic measurements sharpened the picture. Serum lactate was elevated in IgAN (P < 0.001), and serum butyrate was also elevated (P = 0.017). Butyrate is an SCFA; in this setting, the ex vivo work with B cells points to circulating butyrate as a possible contributor to mucosal immune dysregulation in IgAN, acting via changed B-cell homing and weakened regulatory activity.
| Signal | Finding | Statistical value |
|---|---|---|
| Beta diversity (IgAN vs controls) | Different microbial composition | P = 0.001 |
| Blautia enrichment | Replicated in second cohort | P = 0.008 |
| Ruminococcus gnavus group | Replicated in second cohort | P = 0.011 |
| Pyruvate metabolism (ko00620) | Replicated in second cohort | P = 0.005 |
| Serum lactate | Elevated in IgAN | P < 0.001 |
| Serum butyrate | Elevated in IgAN | P = 0.017 |
What the correlations do and do not show
Among patients with IgAN, greater Blautia abundance went hand in hand with higher blood pressure, serum creatinine, and urine protein-to-creatinine ratio (P < 0.05).
The authors frame the butyrate–B-cell finding as a potential mechanism, mediated through altered B-cell homing and impaired regulatory function, and that framing is the appropriate one.
Differential abundance analysis was performed for genera and PICRUSt2-predicted pathways. The functional work involved measuring short-chain fatty acid (SCFA) levels and exposing B cells obtained from patients to SCFAs outside the body.
Where this goes next
The associated microbial and metabolic features remain inconsistently characterized. Taken together, the results point to a possible part for circulating butyrate in mucosal immune dysregulation in IgAN, operating through changed B-cell homing and weakened regulatory activity.
References
- Gut microbial enrichment of Blautia and elevated serum butyrate in IgA nephropathy: an integrated multicenter analysis.
- 16S rRNA sequencing and PICRUSt2 pathway prediction methodology as described in the source study.